Cargando…

Additional cytogenetic abnormalities in patients with newly diagnosed acute promyelocytic leukemia predict inferior event‐free survival

BACKGROUND: The innovative combination of all‐trans retinoic acid (ATRA) and arsenic trioxide (ATO) has established a new chapter of curative approach in acute promyelocytic leukemia (APL). The disease characteristics and prognostic influence of additional cytogenetic abnormalities (ACA) in APL with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Hui, Dong, Hai‐Bo, Zhang, Qi‐Guo, Zhou, Min, Zhang, Qian, Chen, Lan‐Xin, Yuan, Cui‐Ying, Jiang, Ru‐Ru, Liu, Jin‐Wen, Ou‐Yang, Jian, He, Jie, Chen, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524065/ https://www.ncbi.nlm.nih.gov/pubmed/37584196 http://dx.doi.org/10.1002/cam4.6398

Ejemplares similares

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

Newly Diagnosed Acute Promyelocytic Leukemia
por: Avvisati, Giuseppe
Publicado: (2011)

Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic Leukemia
por: Sun, Jianai, et al.
Publicado: (2020)

FISH-negative, cytogenetically cryptic acute promyelocytic leukemia
por: Rashidi, A, et al.
Publicado: (2015)

Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
por: Xu, Fang, et al.
Publicado: (2017)

Cost-effectiveness of the regimen proposed by the International Consortium on Acute Promyelocytic Leukemia for the treatment of newly diagnosed patients with Acute Promyelocytic Leukemia
por: Rodríguez-Rodríguez, Sergio, et al.
Publicado: (2021)

Cytogenetically Cryptic Acute Promyelocytic Leukemia: A Diagnostic Challenge
por: Mohebnasab, Maedeh, et al.
Publicado: (2023)

Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

Intracranial Hemorrhage Secondary to Newly Diagnosed Acute Promyelocytic Leukemia: A Cautionary Tale
por: Peddi, Kanksha, et al.
Publicado: (2022)

Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia
por: Zhao, Shixiang, et al.
Publicado: (2023)

Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics
por: Sahoo, Ranjit Kumar, et al.
Publicado: (2013)

Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
por: Zhuang, Zhe, et al.
Publicado: (2023)

Retrospective Study of Acute Kidney Injury Incidence in Patients with Newly Diagnosed Acute Promyelocytic Leukemia
por: Kamio, Tadashi, et al.
Publicado: (2020)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

Association between FLT3-ITD and additional chromosomal abnormalities in the prognosis of acute promyelocytic leukemia
por: Vu, Minh Phuong, et al.
Publicado: (2022)

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
por: Binder, M, et al.
Publicado: (2017)

Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia
por: Wen, Jingjing, et al.
Publicado: (2022)

Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia
por: Song, Yu-hua, et al.
Publicado: (2017)

A Novel Inclusion Body in Acute Promyelocytic Leukemia
por: Dong, Shu-xu, et al.
Publicado: (2023)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Cytogenetically cryptic PML::RARA fusion in acute promyelocytic leukemia: Testing strategies in the modern era
por: Karlin, Kirill, et al.
Publicado: (2022)

Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
por: Chendamarai, Ezhilarasi, et al.
Publicado: (2015)

Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia
por: Liu, Cheng-cheng, et al.
Publicado: (2015)

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia
por: Zhang, Ye, et al.
Publicado: (2016)

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
por: Aïssata, Tolo Diebkilé, et al.
Publicado: (2013)

Incident adverse events following therapy for acute promyelocytic leukemia
por: Kim, Peter Geon, et al.
Publicado: (2018)

Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
por: Tao, Shandong, et al.
Publicado: (2019)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Terpos, Evangelos, et al.
Publicado: (2022)

P26 LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)
por: Varshavsky Yanovsky, A., et al.
Publicado: (2023)

Chromosomal abnormality of acute promyelocytic leukemia other than PML-RARA: a case report of acute promyelocytic leukemia with del(5q)
por: Imataki, Osamu, et al.
Publicado: (2016)

Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
por: Abramowitz, Julia, et al.
Publicado: (2017)

Acute Promyelocytic Leukemia
por: Thomas, Xavier, et al.
Publicado: (2020)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Age and cytogenetic abnormalities()
por: Souza, Cármino Antonio de
Publicado: (2018)

Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia
por: Wu, Fenfang, et al.
Publicado: (2016)

A complete remission can be achieved despite persistence of abnormal bone marrow promyelocytes in acute promyelocytic leukemia--experience in 2 patients.
por: Kim, S. W., et al.
Publicado: (1993)

The Cytogenetic Landscape of Pediatric Chronic Myeloid Leukemia Diagnosed in Chronic Phase
por: Karow, Axel, et al.
Publicado: (2022)

History of Acute Promyelocytic Leukemia
por: Sanz, Miguel A., et al.
Publicado: (2021)

PB1851: EARLY DEATHS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY FROM A GENERAL HOSPITAL
por: Yohannan, B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m1j66b300be5uf9dpsjv07vvjv